. . "\u0627\u0644\u0642\u0635\u0648\u0631 \u0627\u0644\u0643\u0628\u062F\u064A \u0627\u0644\u062D\u0627\u062F \u0623\u0648 \u0627\u0644\u0641\u0634\u0644 \u0627\u0644\u0643\u0628\u062F\u064A \u0627\u0644\u062D\u0627\u062F (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Acute liver failure)\u200F \u0647\u0648 \u0638\u0647\u0648\u0631 \u0645\u0636\u0627\u0639\u0641\u0627\u062A \u0634\u062F\u064A\u062F\u0629 \u0633\u0631\u064A\u0639\u064B\u0627 \u0628\u0639\u062F \u0627\u0644\u0628\u0648\u0627\u062F\u0631 \u0627\u0644\u0623\u0648\u0644\u0649 \u0644\u0645\u0631\u0636 \u0627\u0644\u0643\u0628\u062F (\u0645\u062B\u0644 \u0627\u0644\u064A\u0631\u0642\u0627\u0646)\u060C \u0648\u064A\u0634\u064A\u0631 \u0625\u0644\u0649 \u062A\u0639\u0631\u064F\u0651\u0636 \u0627\u0644\u0643\u0628\u062F \u0644\u0623\u0636\u0631\u0627\u0631 \u062C\u0633\u064A\u0645\u0629 (\u0641\u0642\u062F\u0627\u0646 \u0648\u0638\u0627\u0626\u0641 80-90% \u0645\u0646 \u062E\u0644\u0627\u064A\u0627 \u0627\u0644\u0643\u0628\u062F). \u0627\u0644\u0645\u0636\u0627\u0639\u0641\u0627\u062A \u0647\u064A \u0627\u0639\u062A\u0644\u0627\u0644 \u0627\u0644\u062F\u0645\u0627\u063A \u0627\u0644\u0643\u0628\u062F\u064A\u060C \u0646\u0642\u0635 \u062A\u0635\u0646\u064A\u0639 \u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0646 (\u062D\u064A\u062B \u062A\u064F\u0642\u0627\u0633 \u0645\u0633\u062A\u0648\u064A\u0627\u062A \u0627\u0644\u0623\u0644\u0628\u064A\u0648\u0645\u064A\u0646 \u0641\u064A \u0627\u0644\u062F\u0645 \u0648\u0648\u0642\u062A \u0627\u0644\u0628\u0631\u0648\u062B\u0631\u0648\u0645\u0628\u064A\u0646 \u0641\u064A \u0627\u0644\u062F\u0645). \u064A\u062D\u062F\u0650\u0651\u062F \u062A\u0635\u0646\u064A\u0641 1993 \u0623\u0646 \u0641\u0631\u0637 \u0627\u0644\u062D\u062F\u0629 \u064A\u0643\u0648\u0646 \u062E\u0644\u0627\u0644 \u0623\u0633\u0628\u0648\u0639\u060C \u0627\u0644\u062D\u0627\u062F \u062E\u0644\u0627\u0644 8-28 \u064A\u0648\u0645\u060C \u0648\u062A\u062D\u062A \u0627\u0644\u062D\u0627\u062F \u062E\u0644\u0627\u06444-12 \u0623\u0633\u0628\u0648\u0639. \u0648\u0647\u0648 \u064A\u0639\u0643\u0633 \u062D\u0642\u064A\u0642\u0629 \u0623\u0646 \u0648\u062A\u064A\u0631\u0629 \u062D\u062F\u0648\u062B \u0627\u0644\u0645\u0631\u0636 \u062A\u0624\u062B\u0631 \u062A\u0623\u062B\u064A\u0631\u064B\u0627 \u0642\u0648\u064A\u064B\u0627 \u0639\u0644\u0649 \u062A\u0642\u062F\u064F\u0651\u0645 \u0627\u0644\u062D\u0627\u0644\u0629 \u0627\u0644\u0645\u0631\u0636\u064A\u0629. \u0643\u0645\u0627 \u0623\u0646 \u0627\u0644\u0645\u0633\u0628\u0628\u0627\u062A \u0648\u0631\u0627\u0621 \u0630\u0644\u0643 \u0647\u064A \u0627\u0644\u0645\u062D\u062F\u062F \u0627\u0644\u0647\u0627\u0645 \u0627\u0644\u0622\u062E\u0631 \u0644\u0644\u0646\u062A\u064A\u062C\u0629."@ar . . "Si definisce insufficienza epatica fulminante o atrofia gialla acuta del fegato l'insufficienza epatica che conduce all'encefalopatia epatica nel giro di 2-3 settimane."@it . . "La insufici\u00E8ncia hep\u00E0tica aguda \u00E9s l'aparici\u00F3 de complicacions greus r\u00E0pidament despr\u00E9s dels primers signes (com la icter\u00EDcia) de malaltia hep\u00E0tica, i indica que el fetge ha patit danys greus (p\u00E8rdua de funci\u00F3 del 80-90% de les c\u00E8l\u00B7lules hep\u00E0tiques). Les complicacions s\u00F3n l'encefalopatia hep\u00E0tica i la s\u00EDntesi de prote\u00EFnes deteriorada (mesurada pels nivells d'alb\u00FAmina s\u00E8rica i el temps de protrombina a la sang). La classificaci\u00F3 de 1993 defineix la hiperaguda com a dins d'una setmana, aguda com a 8-28 dies i subaguda com a 4-12 setmanes; tant la velocitat amb qu\u00E8 es desenvolupa la malaltia com la causa subjacent afecten fortament els resultats."@ca . . . . "Acute liver failure"@en . . . . . . . . . . . . . "Insufficienza epatica acuta"@it . . . "article"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "\uAE09\uC131 \uAC04\uBD80\uC804(\u6025\u6027\u809D\u4E0D\u5168, acute liver failure)\uC740 \uAC04 \uC9C8\uD658\uC758 \uC99D\uC0C1\uC774 \uC788\uC740 \uC9C1\uD6C4 \uC2EC\uAC01\uD55C \uD569\uBCD1\uC99D\uC774 \uBC1C\uC0DD\uD558\uB294 \uAC83\uC73C\uB85C, \uAC04\uC5D0 \uC2EC\uAC01\uD55C \uC190\uC0C1(\uAC04 \uC138\uD3EC \uAE30\uB2A5\uC758 80 ~ 90% \uC190\uC0C1)\uC744 \uC785\uC5C8\uC74C\uC744 \uB098\uD0C0\uB0B8\uB2E4. \uD569\uBCD1\uC99D\uC740 \uAC04\uC131 \uB1CC\uC99D\uACFC \uB2E8\uBC31\uC9C8 \uD569\uC131 \uC7A5\uC560(\uD608\uC561\uC758 \uACFC \uC218\uC900\uC744 \uCE21\uC815\uD55C\uB2E4.)\uB85C \uB098\uD0C0\uB09C\uB2E4. 1993\uB144\uC758 \uBD84\uB958\uC5D0\uC11C\uB294 '\uCD08\uAE09\uC131(hyperacute)'\uC744 1\uC8FC, '\uAE09\uC131(acute)'\uC744 8 ~ 28\uC77C, '\uC544\uAE09\uC131(subacute)'\uC744 4 ~ 12\uC8FC\uB85C \uC815\uC758\uD55C\uB2E4. \uC774\uB294 \uBCD1\uC758 \uC9C4\uD589 \uC18D\uB3C4\uAC00 \uBCD1\uC758 \uC608\uD6C4\uC5D0 \uD070 \uC601\uD5A5\uC744 \uC900\uB2E4\uB294 \uC0AC\uC2E4\uC5D0 \uAE30\uCD08\uD55C\uB2E4. \uBCD1\uC758 \uC6D0\uC778\uC5D0 \uB530\uB77C \uACB0\uACFC \uB610\uD55C \uB2EC\uB77C\uC9C4\uB2E4."@ko . . . "Hepatic encephalopathy,kidney failure,thrombocytopenia,hyponatraemia" . . "Prothrombin time measurement, complete blood count"@en . "Insufici\u00EAncia hep\u00E1tica aguda \u00E9 o aparecimento s\u00FAbito de complica\u00E7\u00F5es graves logo ap\u00F3s os primeiros sinais de doen\u00E7a hep\u00E1tica (como icter\u00EDcia), sendo um indicador de que o f\u00EDgado apresenta les\u00F5es graves (perda de 80-90% da fun\u00E7\u00E3o nas c\u00E9lulas hep\u00E1ticas). As complica\u00E7\u00F5es s\u00E3o encefalopatia hep\u00E1tica e diminui\u00E7\u00E3o da s\u00EDntese proteica."@pt . . . . . "Insufici\u00E8ncia hep\u00E0tica aguda"@ca . . "Insufici\u00EAncia hep\u00E1tica aguda"@pt . . . . . . . . . . . . . . . . "Ostra niewydolno\u015B\u0107 w\u0105troby (\u0142ac. insufficientia hepatis acuta) \u2013 szybkie pogorszenie czynno\u015Bci w\u0105troby u chorych bez marsko\u015Bci, prowadz\u0105ce w okresie kr\u00F3tszym ni\u017C 26 tygodni od pocz\u0105tku objaw\u00F3w do wytworzenia encefalopatii w\u0105trobowej i osoczowych zaburze\u0144 krzepni\u0119cia. Inna definicja m\u00F3wi, \u017Ce ostra niewydolno\u015B\u0107 w\u0105troby to potencjalnie odwracalna, nag\u0142a, trwa\u0142a i post\u0119puj\u0105ca dysfunkcja w\u0105troby (bez wcze\u015Bniejszej choroby w\u0105troby) charakteryzuj\u0105ca si\u0119 wyst\u0105pieniem encefalopatii w ci\u0105gu mniej ni\u017C 4 tygodni od pocz\u0105tk\u00F3w objaw\u00F3w."@pl . . . "Acute liver failure"@en . . . . . . . . . "Insuffisance h\u00E9patique aigu\u00EB"@fr . . "1117766465"^^ . . . . . . . . "570"^^ . "Acute liver failure"@en . . . . . . . . "\u0627\u0644\u0642\u0635\u0648\u0631 \u0627\u0644\u0643\u0628\u062F\u064A \u0627\u0644\u062D\u0627\u062F \u0623\u0648 \u0627\u0644\u0641\u0634\u0644 \u0627\u0644\u0643\u0628\u062F\u064A \u0627\u0644\u062D\u0627\u062F (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Acute liver failure)\u200F \u0647\u0648 \u0638\u0647\u0648\u0631 \u0645\u0636\u0627\u0639\u0641\u0627\u062A \u0634\u062F\u064A\u062F\u0629 \u0633\u0631\u064A\u0639\u064B\u0627 \u0628\u0639\u062F \u0627\u0644\u0628\u0648\u0627\u062F\u0631 \u0627\u0644\u0623\u0648\u0644\u0649 \u0644\u0645\u0631\u0636 \u0627\u0644\u0643\u0628\u062F (\u0645\u062B\u0644 \u0627\u0644\u064A\u0631\u0642\u0627\u0646)\u060C \u0648\u064A\u0634\u064A\u0631 \u0625\u0644\u0649 \u062A\u0639\u0631\u064F\u0651\u0636 \u0627\u0644\u0643\u0628\u062F \u0644\u0623\u0636\u0631\u0627\u0631 \u062C\u0633\u064A\u0645\u0629 (\u0641\u0642\u062F\u0627\u0646 \u0648\u0638\u0627\u0626\u0641 80-90% \u0645\u0646 \u062E\u0644\u0627\u064A\u0627 \u0627\u0644\u0643\u0628\u062F). \u0627\u0644\u0645\u0636\u0627\u0639\u0641\u0627\u062A \u0647\u064A \u0627\u0639\u062A\u0644\u0627\u0644 \u0627\u0644\u062F\u0645\u0627\u063A \u0627\u0644\u0643\u0628\u062F\u064A\u060C \u0646\u0642\u0635 \u062A\u0635\u0646\u064A\u0639 \u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0646 (\u062D\u064A\u062B \u062A\u064F\u0642\u0627\u0633 \u0645\u0633\u062A\u0648\u064A\u0627\u062A \u0627\u0644\u0623\u0644\u0628\u064A\u0648\u0645\u064A\u0646 \u0641\u064A \u0627\u0644\u062F\u0645 \u0648\u0648\u0642\u062A \u0627\u0644\u0628\u0631\u0648\u062B\u0631\u0648\u0645\u0628\u064A\u0646 \u0641\u064A \u0627\u0644\u062F\u0645). \u064A\u062D\u062F\u0650\u0651\u062F \u062A\u0635\u0646\u064A\u0641 1993 \u0623\u0646 \u0641\u0631\u0637 \u0627\u0644\u062D\u062F\u0629 \u064A\u0643\u0648\u0646 \u062E\u0644\u0627\u0644 \u0623\u0633\u0628\u0648\u0639\u060C \u0627\u0644\u062D\u0627\u062F \u062E\u0644\u0627\u0644 8-28 \u064A\u0648\u0645\u060C \u0648\u062A\u062D\u062A \u0627\u0644\u062D\u0627\u062F \u062E\u0644\u0627\u06444-12 \u0623\u0633\u0628\u0648\u0639. \u0648\u0647\u0648 \u064A\u0639\u0643\u0633 \u062D\u0642\u064A\u0642\u0629 \u0623\u0646 \u0648\u062A\u064A\u0631\u0629 \u062D\u062F\u0648\u062B \u0627\u0644\u0645\u0631\u0636 \u062A\u0624\u062B\u0631 \u062A\u0623\u062B\u064A\u0631\u064B\u0627 \u0642\u0648\u064A\u064B\u0627 \u0639\u0644\u0649 \u062A\u0642\u062F\u064F\u0651\u0645 \u0627\u0644\u062D\u0627\u0644\u0629 \u0627\u0644\u0645\u0631\u0636\u064A\u0629. \u0643\u0645\u0627 \u0623\u0646 \u0627\u0644\u0645\u0633\u0628\u0628\u0627\u062A \u0648\u0631\u0627\u0621 \u0630\u0644\u0643 \u0647\u064A \u0627\u0644\u0645\u062D\u062F\u062F \u0627\u0644\u0647\u0627\u0645 \u0627\u0644\u0622\u062E\u0631 \u0644\u0644\u0646\u062A\u064A\u062C\u0629."@ar . . "El fallo hep\u00E1tico fulminante se define cl\u00E1sicamente como un trastorno de inicio s\u00FAbito e intenso de la funci\u00F3n del h\u00EDgado, que se pone de manifiesto con ictericia, y es seguido de encefalopat\u00EDa hep\u00E1tica, en ausencia de da\u00F1o hep\u00E1tico previo. Es denominada tambi\u00E9n atrofia aguda amarilla."@es . . . . "1226250"^^ . . . . . . . . . . . . "37213"^^ . . . "Ostra niewydolno\u015B\u0107 w\u0105troby"@pl . . . . "article"@en . . . . "Acute liver failure from Marburg virus, a rare cause"@en . . . . . . . "L\u2019insuffisance h\u00E9patique aig\u00FCe (ou IHA), parfois appel\u00E9e h\u00E9patite fulminante est une alt\u00E9ration aigu\u00EB grave de la fonction h\u00E9patocellulaire survenant en moins de 8 semaines, et sans maladie h\u00E9patique pr\u00E9existante. La d\u00E9finition peut cependant varier en nuances suivant les publications. L'origine peut \u00EAtre toxique (m\u00E9dicaments, champignons v\u00E9n\u00E9neux) ou infectieuse (h\u00E9patites virales). Les premi\u00E8res cons\u00E9quences sont des troubles majeurs de l'h\u00E9mostase entra\u00EEnant un risque h\u00E9morragique multivisc\u00E9ral. Son pronostic est extr\u00EAmement s\u00E9v\u00E8re."@fr . . . "177354"@en . . . . . "\uAE09\uC131 \uAC04\uBD80\uC804(\u6025\u6027\u809D\u4E0D\u5168, acute liver failure)\uC740 \uAC04 \uC9C8\uD658\uC758 \uC99D\uC0C1\uC774 \uC788\uC740 \uC9C1\uD6C4 \uC2EC\uAC01\uD55C \uD569\uBCD1\uC99D\uC774 \uBC1C\uC0DD\uD558\uB294 \uAC83\uC73C\uB85C, \uAC04\uC5D0 \uC2EC\uAC01\uD55C \uC190\uC0C1(\uAC04 \uC138\uD3EC \uAE30\uB2A5\uC758 80 ~ 90% \uC190\uC0C1)\uC744 \uC785\uC5C8\uC74C\uC744 \uB098\uD0C0\uB0B8\uB2E4. \uD569\uBCD1\uC99D\uC740 \uAC04\uC131 \uB1CC\uC99D\uACFC \uB2E8\uBC31\uC9C8 \uD569\uC131 \uC7A5\uC560(\uD608\uC561\uC758 \uACFC \uC218\uC900\uC744 \uCE21\uC815\uD55C\uB2E4.)\uB85C \uB098\uD0C0\uB09C\uB2E4. 1993\uB144\uC758 \uBD84\uB958\uC5D0\uC11C\uB294 '\uCD08\uAE09\uC131(hyperacute)'\uC744 1\uC8FC, '\uAE09\uC131(acute)'\uC744 8 ~ 28\uC77C, '\uC544\uAE09\uC131(subacute)'\uC744 4 ~ 12\uC8FC\uB85C \uC815\uC758\uD55C\uB2E4. \uC774\uB294 \uBCD1\uC758 \uC9C4\uD589 \uC18D\uB3C4\uAC00 \uBCD1\uC758 \uC608\uD6C4\uC5D0 \uD070 \uC601\uD5A5\uC744 \uC900\uB2E4\uB294 \uC0AC\uC2E4\uC5D0 \uAE30\uCD08\uD55C\uB2E4. \uBCD1\uC758 \uC6D0\uC778\uC5D0 \uB530\uB77C \uACB0\uACFC \uB610\uD55C \uB2EC\uB77C\uC9C4\uB2E4."@ko . . . . . . . . ""@en . . . . . . . . . . "L\u2019insuffisance h\u00E9patique aig\u00FCe (ou IHA), parfois appel\u00E9e h\u00E9patite fulminante est une alt\u00E9ration aigu\u00EB grave de la fonction h\u00E9patocellulaire survenant en moins de 8 semaines, et sans maladie h\u00E9patique pr\u00E9existante. La d\u00E9finition peut cependant varier en nuances suivant les publications. L'origine peut \u00EAtre toxique (m\u00E9dicaments, champignons v\u00E9n\u00E9neux) ou infectieuse (h\u00E9patites virales). Les premi\u00E8res cons\u00E9quences sont des troubles majeurs de l'h\u00E9mostase entra\u00EEnant un risque h\u00E9morragique multivisc\u00E9ral. Son pronostic est extr\u00EAmement s\u00E9v\u00E8re. Le traitement est d'abord, quand c'est possible, celui de la cause, mais il consiste dans la plupart des cas en une transplantation h\u00E9patique en urgence."@fr . . . . . . . . . "Insufici\u00EAncia hep\u00E1tica aguda \u00E9 o aparecimento s\u00FAbito de complica\u00E7\u00F5es graves logo ap\u00F3s os primeiros sinais de doen\u00E7a hep\u00E1tica (como icter\u00EDcia), sendo um indicador de que o f\u00EDgado apresenta les\u00F5es graves (perda de 80-90% da fun\u00E7\u00E3o nas c\u00E9lulas hep\u00E1ticas). As complica\u00E7\u00F5es s\u00E3o encefalopatia hep\u00E1tica e diminui\u00E7\u00E3o da s\u00EDntese proteica."@pt . "\u0641\u0634\u0644 \u0643\u0628\u062F\u064A \u062D\u0627\u062F"@ar . . . . . . "El fallo hep\u00E1tico fulminante se define cl\u00E1sicamente como un trastorno de inicio s\u00FAbito e intenso de la funci\u00F3n del h\u00EDgado, que se pone de manifiesto con ictericia, y es seguido de encefalopat\u00EDa hep\u00E1tica, en ausencia de da\u00F1o hep\u00E1tico previo. Es denominada tambi\u00E9n atrofia aguda amarilla."@es . "Acute liver failure is the appearance of severe complications rapidly after the first signs (such as jaundice) of liver disease, and indicates that the liver has sustained severe damage (loss of function of 80\u201390% of liver cells). The complications are hepatic encephalopathy and impaired protein synthesis (as measured by the levels of serum albumin and the prothrombin time in the blood). The 1993 classification defines hyperacute as within 1 week, acute as 8\u201328 days, and subacute as 4\u201312 weeks; both the speed with which the disease develops and the underlying cause strongly affect outcomes."@en . "Ostra niewydolno\u015B\u0107 w\u0105troby (\u0142ac. insufficientia hepatis acuta) \u2013 szybkie pogorszenie czynno\u015Bci w\u0105troby u chorych bez marsko\u015Bci, prowadz\u0105ce w okresie kr\u00F3tszym ni\u017C 26 tygodni od pocz\u0105tku objaw\u00F3w do wytworzenia encefalopatii w\u0105trobowej i osoczowych zaburze\u0144 krzepni\u0119cia. Inna definicja m\u00F3wi, \u017Ce ostra niewydolno\u015B\u0107 w\u0105troby to potencjalnie odwracalna, nag\u0142a, trwa\u0142a i post\u0119puj\u0105ca dysfunkcja w\u0105troby (bez wcze\u015Bniejszej choroby w\u0105troby) charakteryzuj\u0105ca si\u0119 wyst\u0105pieniem encefalopatii w ci\u0105gu mniej ni\u017C 4 tygodni od pocz\u0105tk\u00F3w objaw\u00F3w. W obrazie klinicznym dominuje triada objaw\u00F3w: \u017C\u00F3\u0142taczka, zaburzenia krzepni\u0119cia krwi, zaburzenia \u015Bwiadomo\u015Bci."@pl . . . . . . . . . . "Hepatitis fulminante"@es . . . . . "La insufici\u00E8ncia hep\u00E0tica aguda \u00E9s l'aparici\u00F3 de complicacions greus r\u00E0pidament despr\u00E9s dels primers signes (com la icter\u00EDcia) de malaltia hep\u00E0tica, i indica que el fetge ha patit danys greus (p\u00E8rdua de funci\u00F3 del 80-90% de les c\u00E8l\u00B7lules hep\u00E0tiques). Les complicacions s\u00F3n l'encefalopatia hep\u00E0tica i la s\u00EDntesi de prote\u00EFnes deteriorada (mesurada pels nivells d'alb\u00FAmina s\u00E8rica i el temps de protrombina a la sang). La classificaci\u00F3 de 1993 defineix la hiperaguda com a dins d'una setmana, aguda com a 8-28 dies i subaguda com a 4-12 setmanes; tant la velocitat amb qu\u00E8 es desenvolupa la malaltia com la causa subjacent afecten fortament els resultats."@ca . . . . . . . . . . . "K72."@en . . . . "Si definisce insufficienza epatica fulminante o atrofia gialla acuta del fegato l'insufficienza epatica che conduce all'encefalopatia epatica nel giro di 2-3 settimane."@it . . . . "D017114"@en . . . . . . . . . . "Acute liver failure is the appearance of severe complications rapidly after the first signs (such as jaundice) of liver disease, and indicates that the liver has sustained severe damage (loss of function of 80\u201390% of liver cells). The complications are hepatic encephalopathy and impaired protein synthesis (as measured by the levels of serum albumin and the prothrombin time in the blood). The 1993 classification defines hyperacute as within 1 week, acute as 8\u201328 days, and subacute as 4\u201312 weeks; both the speed with which the disease develops and the underlying cause strongly affect outcomes."@en . . . . . . . . . . . . "\uAE09\uC131 \uAC04\uBD80\uC804"@ko . . . "570" . . . "K72." . . "D017114" . . "177354"^^ . . . . . . . . . . .